Trial intelligence / Profile preview

Fruquintinib + paclitaxel vs paclitaxel in second-line advanced gastric or GEJ adenocarcinoma

CTR20170702Phase 3Completed

Sponsor
HUTCHMED
Start
Jul 2017
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

A Phase 3 trial of fruquintinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by HUTCHMED. Started Jul 2017; status: completed.

02

Drugs

fruquintinib
03

Conditions

gastric adenocarcinomagastroesophageal junction adenocarcinoma

Beyond the preview

Go deeper on CTR20170702.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20170702.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call